Article
Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com
All News
Article
An open-label extension of the ASSET trial (abatacept in diffuse cutaneous systemic sclerosis) showed continued safety with significant improvements in the modified Rodnan Skin Score (mRSS) at 12 months, suggesting abatacept (ABA) may benefit early systemic sclerosis (SSc).
Article
While there have been several promising new agents for systemic sclerosis, many have failed - with all noting the difficulties in appropriate outcomes and endpoints for clinical trials. With this in mind, the FDA was interested in hearing patients’ perspectives on systemic sclerosis and new drug development, and held a virtual meeting on 10/13/20.
Article
The DISCOVER‐2 trial has shown that guselkumab, an interleukin‐23p19 was shown to be safe and effective in biologic‐naïve psoriatic arthritis (PsA) patients in a one year study.
Article
JAMA Internal Medicine has published a review showing that most currently approved therapies for fibromyalgia (FM) do not have high-quality evidence to support their use; with some reducing pain or improving quality of life (QOL) in the short term, but overall effect size is not impressive.
Article
Vedolizumab (Entyvio) was superior to infliximab (Remicade) for treating immune-mediated diarrhea and colitis (IMDC), a researcher reported.
Article
A full read review of immune-mediated necrotizing myopathy is portrayed as a distinct subtype of inflammatory myopathies first described in 2004.
Article
A new short‐term follow‐up study has shown no significant difference in outcomes and quality measures in patients with RA who were managed by telemedicine (compared to usual in-person care).
Dr. John Cush
Tweet
QD104 - You Are So Not Disabled
QD Clinic - Lessons from the clinic
Grappling with Disability Letter Requests
Features Dr. Jack Cush
https://t.co/Vg5i9rHyKN
Dr. John Cush
Tweet
Metaanalysis of 7 cohort studies, 34 029 biologic & 135370 biologic-naive Pts (RA, PsO, IBD) looked at risk of melanoma (vs conventional Rx). Found no statistically significant increase risk for melanoma w/ biologics (eg RA RR 1.2; 95% CI, 0.83-1.74) https://t.co/rnZwzqE8m2
Dr. John Cush
Tweet
Intnl psoriasis registry reports Less hospitalization in PSO on biologics (16% vs 33%); higher HR 2.8 on non-biologics. 374 Psoriasis pts w/ COVID-19, 71% on biologic, 18% non-biologic & 10% no systemic Rx. 93% fully recovered. 21% hospitalized, 2% died. https://t.co/xLaPrkfDCf
Dr. John Cush
Tweet
25 pts w/ refractory Juvenile dermatomyositis (JDM) were treated w/ JAK inhib (tofacitinib, ruxolitinib) - all showed improved rashes, including 66.7% with complete resolution; 40% had decreased muscle strength; 28% discontinued glucocorticoids https://t.co/wln0FrI0Iz
Dr. John Cush
Tweet
Population study from NY of 168,234 hip replacements and 308,477 knee TKAs showed that total joint arthroplasty was associated with a 34-44% decrease risk of falls (THA HR 0.56; TKA HR 0.66). Risk of falls incr w/ age- 70-79 yrs (HR4.3), 80+ yrs (HR 5.5) https://t.co/KeejsfGEjn
Dr. John Cush
Tweet
Barer-Flood Prize
Headshot of
Canadian Instit of Health has awarded Dr. Peter Tugwell Barer-Flood Prize, recognizing and exceptional career with a substantial impact on health care policy research, policy, delivery. He is a founding member of Cochrane . https://t.co/qxqUrdEFYz https://t.co/HOuLw4DxP3
Dr. John Cush
Tweet
Autoantibodies can be found in COVID-19 ptas (including ANA, RF, -RNP centromere and antibobides against phospholipids (3/52), prothrombin (2/52), and c-ANCA (2/52)) (THIS IS A PREPRINT) https://t.co/kN6hVMiNt3 https://t.co/4yNJJhOxXP
Dr Philip Robinson
Tweet
ACTIV-1 run by the @NIH will test rheum drugs infliximab and abatacept in COVID-19. This is great news. https://t.co/IITzGTuxEC
Peter Nash
Tweet
Incidence & Risk VTE Among Pts RA Enrolled in Upadacitinib Trial Program https://t.co/zCuWHZXV4h #VTE #Upadacitinib balanced VTE across trial programme in the expected 0.5-0.8/100 pt yrs range - past VTE & BMI risk factors, no mention COX2s - is VTE Jak2 effect or class effect?
Dr. John Cush
Tweet
New research shows potential utility of plasma specialized pro-resolving mediator (SPM; like RvD4, 10S, 17S-diHDPA, 15R-LXA4 and MaR1n-3 DPA) concentrations as biomarkers to predict DMARD responsiveness in #RA. https://t.co/WQb57EON10
Dr. John Cush
Tweet
Review of 127 pts w/ diagnostic criteria for palindromic rheumatism - Most affected JTS were wrist, knee, MCP; 34% later developed CTD (28% RA, 2% lupus 3% other CTD). Progression predicted by +RF (HR 2.9), PIP (HR 2.4), Wrist (HR 2.5) & female (HR 2.2)
Dr. John Cush
Tweet
Safety of nintedinib (NIN)in PSS-ILD - 576 PSS pts given NIN 150 mg bid or PBO x52wks. Dose lowered to 100 mg bid for AE. Diarrhea seen in 76% of NIN and 32% in PBO (d/c in 6.9% & 0.3%). Dose reduction in 48% & 12%. RCT discontinuation in 16% & 8.7% https://t.co/v5NxwlHu37
